The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ ...

Get ready for a deep dive into colchicine and cardiovascular disease! We’ll examine the RCT data, and then pivot to discuss ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...

Please provide your email address to receive an email when new articles are posted on . Patients with elevated levels of high-sensitivity C-reactive protein are at risk for CV events. Low-dose ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...

Scilex Holding Company announced the publication of important dosing adjustments for GLOPERBA®, its liquid oral colchicine product for gout management, in a peer-reviewed journal. GLOPERBA® is unique ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...